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a  b  s  t  r  a  c  t
Policymakers  have  cited  several  barriers  to  using  evidence  in  policy  decisions,  including
lack  of  research  relevance  and  timeliness.  In recent  years,  several  reports  have  focused  on
the  successes  and  challenges  of  researcher–policymaker  collaborations,  a form  of policy
engagement  intended  to  help  overcome  barriers  to  the  use  of research  evidence  in pol-
icymaking.  Although  these  reports  often  demonstrate  an  increase  in  research  relevance,
rarely do they  provide  concrete  methods  of enhancing  research  timeliness,  which  is  surpris-
ing given  policymakers’  expressed  need  to  receive  “rapid-response”  research.  Additionally,
the impact  of  researcher–policymaker  collaborations  is  not  well-discussed.  In this  paper,
we aim  to describe  the  collaboration  between  the  Ontario  Drug  Policy  Research  Network
(ODPRN)  and its policymaker  partner,  the Ontario  Public  Drug  Program  (OPDP),  with  a par-
ticular  focus  on  the  ODPRN’s  research  methodology  and  unique  rapid-response  approach
for policy  engagement.  This  approach  is  illustrated  through  a speciﬁc  case  example  regard-
ing drug  funding  policies  for  pulmonary  arterial  hypertension.  Moreover,  we  discuss  the
impact  of  the  ODPRN’s  research  on  pharmaceutical  policy  and  lessons  learned  throughout
the  ODPRN  and  OPDP’s  ﬁve-year  partnership.  The  described  experiences  will  be valuable
to those  seeking  to enhance  evidence  uptake  in  policymaking  for immediate  policy  needs.
©  2014  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under
the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).∗ Corresponding author. Tel.: +1 4168646060x77522.
E-mail address: khans@smh.ca (S. Khan).
http://dx.doi.org/10.1016/j.healthpol.2014.06.007
0168-8510/© 2014 The Authors. Published by Elsevier Ireland Ltd. Th
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Evidence-informed policymaking is recognized as an
important tool to improve health outcomes. For example,
evidence-informed anti-tobacco policies partly con-
tributed to a signiﬁcant decrease in tobacco use [1], and the
consequent decline in lung cancer-related deaths [2] and
is is an open access article under the CC BY-NC-ND license
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ospital admissions for childhood asthma [3]. Although
here is persistent advocacy for evidence-informed poli-
ymaking, the challenges of utilizing evidence in policy
re well documented [4]. Policymakers regularly cite
ack of timeliness and relevance of research as barriers to
onsidering evidence in policy decisions [5–8]. The absence
f ongoing communication between researchers and poli-
ymakers [5] poses an additional challenge to developing
vidence-informed policy, as interaction among these
roups is necessary to enhance research relevance.
Several established models of researcher–policymaker
ollaborations are designed to overcome these challenges
9]. Among the most successful is the interactive model
9–11], in which continuous researcher–policymaker
nteraction and collaboration facilitate the process of
roducing policy-relevant research ﬁndings [12]. As
esearcher–policymaker collaborations become more
ommon, understanding existing interactive and col-
aborative methods is imperative to optimizing future
ndeavours. To date, most reports describe the potential
uccesses and challenges of researcher–policymaker
nteractions [5,10] rather than speciﬁc methods of collab-
ration. Two examples of exceptions include a report on
he partnership between a mental health research unit
nd the mental health reform branch of the Ontario gov-
rnment [13]; and an Australian researcher–policymaker
ollaboration focused on case-mix classiﬁcation of sub-
cute and acute patients in Australia [14]. Each of these
ollaborations focused on enhancing communication
etween policymakers and researchers through regular
eetings and forums to inform research questions and
otentially impact policy directions. These examples have
emonstrated successful policy engagement, but there are
 few notable limitations. First, reports on research–policy
ollaborations rarely provide a comprehensive description
f the impact of the collaboration, with only a few exam-
les of ongoing impact assessment evident in the available
iterature; for example, the integration of research into
harmaceutical policy systems in Stockholm, Sweden
15,16]. Second, many descriptions of partnerships focus
n engaging with policymakers while conducting tradi-
ional research studies—therefore, the research typically
pans two years or longer. Given that policymakers have
xpressed a desire for a “rapid-response” research program
hat could be consulted for these pressing policy concerns
17], describing the experiences of such a program is
ssential.
The Ontario Drug Policy Research Network (ODPRN),
 collaboration between policymakers and researchers,
eﬂects the principles of the interactive model while
ncorporating a rapid-response approach. Its goals are
o provide timely, high-quality, policy-relevant research
ndings to policymakers, with the ultimate goal of safe
nd cost-effective use of pharmaceutical therapies. The
urrent paper highlights the ODPRN as a case example
f a researcher–policymaker collaboration using a rapid-
esponse method that has not been reported elsewhere
n the literature. We  describe the ODPRN’s research pro-
esses, the impact of its research, and lessons learned
hroughout its ﬁve-year collaboration with its policymaker
artner.17 (2014) 392–398 393
2. Methods: The ODPRN rapid-response research
approach
2.1. Formation of the researcher–policymaker
partnership
The ODPRN was initiated by researchers who  had prior
experience interacting with drug policymakers. Aware
of the challenges drug policymakers often faced when
seeking timely research to inform their policies, these
researchers conceptualized a method of conducting rapid
pharmacoepidemiological research in response to imme-
diate policymaker needs. In 2008, the ODPRN was funded
by the Ontario Ministry of Health and Long-Term Care
(MOHLTC) to implement their model of rapid-response
research in collaboration with policymakers. The funding
opportunity was designed to facilitate interactive partner-
ships; thus, it enabled the ODPRN to secure policymaker
collaborators at the Ontario Public Drug Program (OPDP),
who had limited capacity to conduct analyses that were rel-
evant to their policy needs. The OPDP is a division within
the MOHLTC responsible for the province’s nearly $5 bil-
lion (CAD) publicly funded drug beneﬁt programs such as
the Ontario Drug Beneﬁt (ODB) Program, which provides
drug coverage to individuals receiving social assistance, the
elderly (over 65 years of age), residents of homes for spe-
cial and long-term care, and people receiving professional
home care services. Through its expert advisory committee,
the Committee to Evaluate Drugs (CED), the OPDP governs
the approval process for drugs within program formula-
ries. As such, the OPDP requires timely and evidence-based
information on effectiveness, cost-effectiveness and bud-
get impact to form decisions on funding schemes.
2.2. ODPRN structure
To conduct rapid-response research, a unique organi-
zational structure was  developed by ODPRN researchers
(Fig. 1) consisting of three main units:
(1) The Rapid Response Unit (RRU) is comprised of epi-
demiologists, a project manager, and biostatisticians
whose primary function is to work with policymakers
to efﬁciently respond to research requests using linked
population-level information from datasets housed at
the Institute for Clinical Evaluative Sciences (ICES).
These linked databases contain healthcare services data
for the entire population of Ontario (approximately 13
million people) since 1988. This includes demographic,
physician claims, emergency department utilization,
hospitalization, and drug data for ODB program recipi-
ents (approximately 2.5 million people).
(2) The Core Academic Unit (CAU) is composed of
researchers (both clinician–researchers and others)
and trainees in the Student Training Program who col-
laborate with the RRU in fulﬁlling policymaker research
requests, as well as addressing their own research ques-
tions through traditional academic research.
(3) The Knowledge Translation Unit (KTU) is comprised
of knowledge translation (KT) specialists with expe-
rience and training in implementation and research
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DPRN stFig. 1. O
dissemination. The KTU disseminates the ODPRN’s
research ﬁndings to target knowledge users and stake-
holders, including policymakers, researchers, clinicians
and the public.
By design, policymaker requests account for up to 70%
of the ODPRN’s research activities. Remaining activities are
dedicated to academic research initiated by CAU members.
The availability of methodological expertise and opera-
tional infrastructure to clinical researchers is an important
driver of CAU member engagement.
2.3. The ODPRN research process
The ODPRN consulted with the OPDP to determine com-
munication processes and to describe data availability and
project scope. Given that ongoing communication is the
gold standard of successful partnerships [12], the collab-
oration established a formal monthly meeting schedule
and appointed a key OPDP contact to attend meetings and
engage in informal communication (e.g. e-mail, phone)
with the ODPRN. These processes frame the ODPRN’s
rapid-response research methods (Fig. 2), including: (1)
clariﬁcation and reﬁnement of the research question; (2)
streamlined data collection and analysis; and (3) effective
communication of research ﬁndings.
2.3.1. Clariﬁcation and reﬁnement of the research
questionIn determining which policies or policy changes are
required, the OPDP considers various sources of infor-
mation including clinical trial evidence, clinical expertise
and opinions/experiences of stakeholders (e.g. patients,ructure.
pharmacists). ODPRN evidence is requested when current
population-level information on real-world drug safety and
drug utilization patterns is required to inform policies.
The OPDP submits research requests, consisting of one
or a series of questions relating to a particular policy under
consideration, and required timelines to the RRU Lead (Box
1a, Fig. 2). The ODPRN and the OPDP collaborate to reﬁne
the objectives, conﬁrm project feasibility given data avail-
ability and requested timelines, and ensure that the output
will appropriately address the OPDP’s speciﬁc needs (Box
2a and 2b, Fig. 2). To facilitate this process, the ODPRN pre-
pares project proposals that outline methods, potentially
relevant outcomes, limitations of the proposed analyses,
and mock tables and ﬁgures of the anticipated output.
2.3.2. Streamlined data collection and analysis
Rapid analyses are conducted with a typical completion
time of 5–10 business days (Box 3, Fig. 2). The speed of the
research response is facilitated by several factors. First, the
ODPRN utilizes readily available data from linked admin-
istrative databases, which signiﬁcantly shortens the time
period for data collection. Second, a streamlined research
ethics process is in place with the ODPRN’s home insti-
tution when only administrative data is used for research
purposes, with research ethics approval feasible within 2
to 3 days. Third, the ODPRN has developed templates of
analytic plans for frequently conducted study designs. This
allows for the ODPRN’s epidemiologists to rapidly gener-
ate detailed documents that outline all necessary analytical
parameters (e.g. cohort size, time frames, outcomes of
interest) for the analyst. Finally, dedicated analysts who are
familiar with standard approaches utilized in responding to
policymaker requests enable rapid analyses.
S. Khan et al. / Health Policy 117 (2014) 392–398 395
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.3.3. Effective communication of research ﬁndings
Results are reported conﬁdentially in a format based
n the expressed preferences of the OPDP (Box 3, Fig. 2).
he analyses are summarized in one to two pages, begin-
ing with the key ﬁndings, followed by the scope of the
ssue and policy implications. This text is followed by sup-
orting tables and ﬁgures, and ﬁnally the methodological
etails. These reports are written to facilitate understand-
ng of methods and interpretation of results. In addition to
roducing reports, the ODPRN may  be invited to present
heir results at OPDP and CED meetings, which extends the
issemination of the ﬁndings to key decision makers (Box
b, Fig. 2). Furthermore, the OPDP recognizes the value of
eporting ﬁndings in peer-reviewed publications; there-
ore, ODPRN reports are not circulated publically and a
ajority of reports are formatted and submitted as aca-
emic publications (Box 4a, Fig. 2). The rapid-response
esearch process is primarily driven by OPDP requests and
ocuses on pharmacoepidemiology. However, an alterna-
ive approach to conducting research and disseminating
esults to the OPDP occurs through the CAU. Investigator-
ed research questions are proposed at bi-monthly ODPRN
eetings (Box 1b, Fig. 2), and any completed projects that
ay  be of interest to policymakers are reported to the
PDP, while also being published as peer-reviewed aca-
emic publications (Box 4c, Fig. 2). Other dissemination
fforts include posting ‘Research Minutes’—one-page sum-
aries of ODPRN publications targeting knowledge usersearch process
such as policymakers, clinicians and the general public—on
the ODPRN website (www.odprn.ca) (Box 5, Fig. 2).
3. Case example: Funding for pulmonary arterial
hypertension (PAH) pharmacotherapy in Ontario
Pulmonary arterial hypertension (PAH) is a rare and
potentially life-threatening condition. Prior to 2010, the
OPDP only funded PAH monotherapy (i.e. one drug at
one time) due to the lack of evidence at the time on the
effectiveness and safety of PAH combination therapy (i.e.
multiple drugs at one time). Clinicians and patients advo-
cated to the MOHLTC that this was  an impediment to
optimal care.
A multi-disciplinary sub-committee of the CED was  cre-
ated to address PAH drug funding schemes for the OPDP. To
help inform this policy revision process and gain insight on
population-level patterns of PAH drug utilization, the OPDP
submitted a research request to the ODPRN in November
2009, after which the ODPRN rapid-response approach was
initiated.
3.1. Clariﬁcation and reﬁnement of the research questionThe OPDP key contact and two ODPRN scientiﬁc leads
attended a series of CED sub-committee meetings to reﬁne
the research questions. The key analyses that were dis-
cussed focused on understanding current PAH utilization
396 S. Khan et al. / Health Policy 117 (2014) 392–398
Table 1
Summary of ﬁndings and related policy revisions for pulmonary arterial hypertension (PAH) pharmacotherapy in Ontario.
ODPRN analysis ODPRN key ﬁndings PAH drug policy change (from the Ontario Ministry of
Health and Long-Term Care)
Prescribing trends
according to
geography and
specialty
Approximately 84% of PAH drugs are initially prescribed by
a  physician practicing at, or close to, one of ﬁve provincial
cardiology specialist centres i.e. Ontario Centres of
Excellence
Almost three-quarters (73%) of patients starting a PAH
drug receive their ﬁrst prescription from a respirologist
Requests must be from a recognized PAH referral centre:
Toronto General Hospital/University Health Network,
Kingston General Hospital, London Health Sciences Centre,
Hamilton Health Sciences, Ottawa Civic Hospital/Ottawa
Heart Institute
PAH  drug utilization
trends
Three most common PAH drugs utilized in the third
quarter of 2009 were bosentan (60%), sildenaﬁl (23%) and
epoprostenol (13%)
Combination therapy was prevalent among only 5% of
individuals prescribed PAH drugs in the 30 months prior to
the OPDP funding change
Post-funding change, 22% of people received combination
tre of
verall in
Combination therapy may  be considered for patients who
have not achieved treatment targets after at least three
months of single agent therapy (monotherapy) with a
PAH-speciﬁc drug. Drugs used in combination must be
from different classes (i.e., ERA, PDE-5 inhibitor,
prostanoid)therapy, 92% initiated therapy at/near a Cen
Excellence, and there was  no reduction in o
of  PAH drugs
patterns and costs, determining whether any combination
therapy was currently being prescribed (despite funding
restricted to monotherapy only), and to examine the poten-
tial impact of restricting the initiation of PAH drugs to
prescribers at Ontario Centres of Excellence (i.e. PAH spe-
cialist centres).
3.2. Streamlined data collection and analysis
After determining the scope of the research request,
data were retrieved from appropriate provincial databases.
Analyses were conducted using the described rapid-
response procedures.
3.3. Effective communication of research ﬁndings
By February 2010, the ODPRN had distributed three
reports to the OPDP and CED PAH sub-committee, high-
lighting their key results (Table 1). Overall, it was found that
the vast majority of initiation was occurring in or near Cen-
tres of Excellence, and that existing combination therapy
was rare.
3.4. PAH funding policy implications
PAH drug funding changes were enacted in June 2010
(Table 1); funding was expanded to include combination
therapy of selected PAH drugs, and PAH drug initiation was
restricted to Ontario’s ﬁve Centres of Excellence. Various
sources of information were used by the CED to inform
these policies, including randomized controlled trials on
the harms and beneﬁts of combination therapy (of which
there is limited evidence), and input from specialists, drug
manufacturers and patient advocacy groups. In addition to
this information, the CED considered the ODPRN’s ﬁndings
on real-world prescribing patterns and utilization of PAH
drugs, which was stated to have signiﬁcantly contributed
to the adjustment of funding criteria given that the OPDP
was previously unaware of actual prescribing and usage
patterns in Ontario (OPDP, personal communication, July 5,
2012). In particular, the ﬁnding that 84% of people initiated
their PAH therapy within or close to a Centre of Excellenceitiation
conﬁrmed for the OPDP that the new restrictions would
not introduce substantial hardship or disruption for newly
diagnosed PAH patients.
3.5. Impact of ODPRN research
Between September 1, 2008 and June 1, 2013, the
ODPRN has successfully completed 26 research requests
and submitted a total of 59 reports to the OPDP (i.e. one
research request may  result in multiple reports and policy-
relevant CAU research has also been provided to the OPDP
as a report). Additionally, the ODPRN has published 57
manuscripts based on both policymaker research requests
and CAU work, some of which received considerable atten-
tion at the clinical, public and policy levels [18–20].
In addition to producing policy-relevant research, the
ODPRN measures the potential impact of OPDP policies that
were informed by ODPRN evidence. For example, analy-
ses were conducted by the ODPRN examining PAH drug
prescribing and utilization patterns after the enactment of
revised polices in June 2010 to evaluate the PAH funding
changes. Preliminary ﬁndings show that 22% of individuals
on PAH medications were prescribed combination therapy
in the 30 months following the OPDP funding change rel-
ative to 5% of individuals on PAH medications prior to the
OPDP funding change, demonstrating a fourfold increase
in PAH combination therapy (Report on Pulmonary Arte-
rial Hypertension Therapy in Ontario, ODPRN 2012). Recent
studies show that for many individuals, increased access to
combination therapy for PAH may  improve clinical wors-
ening (deﬁned broadly as all-cause death, hospitalization
or disease progression) and exercise capacity [21–23], thus
potentially also improving quality of life [24]. This exam-
ple demonstrates ﬁrst that policy changes resulting in
increased access to therapies deemed to be clinically ben-
eﬁcial for certain patients can be informed by ODPRN
research, and second that researchers can continue to work
policymakers following policy implementation to evaluate
impact.
Perhaps one of the most unique aspects of the partner-
ship is that the ODPRN is able to fulﬁll research requests on
a broad range of topics in drug policy due to the diversity
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f expertise in its membership (e.g. clinicians, pharmacists,
ontent experts, health economic experts, biostatisticians,
pidemiologists), and its ability to quickly seek the advice
f external experts when needed. This collaboration is in
ontrast to most researcher–policymaker collaborations
hat often focus on providing research results for one
opic. As a result, the ODPRN has produced important
esearch results in various other policy areas, including
iabetes treatment and monitoring, and opioid analgesics.
or example, a series of ODPRN studies investigating the
rescribing and safety of opioids informed the OPDP’s
ecision to further restrict funding for long-acting oxy-
odone (OPDP, personal communication, July 5, 2012) and
nformed legislation around the use of opioid analgesics
25]. Thus, it is apparent that the ODPRN’s research has
mpacted decision making in many areas of pharmaceutical
rug policy through their partnership with the OPDP.
. Discussion
.1. Lessons learned about researcher–policymaker
ollaboration
The ODPRN’s rapid-response research methods com-
rise a unique approach to addressing immediate policy
oncerns and ﬁll a gap in reported researcher–policymaker
ollaborations. For example, Canadian pharmaceutical
rug policymakers described a “ﬁreﬁghting” culture in
hich political and societal pressures created a press-
ng need for policy change, and desired a rapid-response
esearch program that could be consulted for particular
harmaceutical policy concerns [17]. The ODPRN model of
esearch addresses an expressed need for these particu-
ar policy questions. Designing methods that are at once
esponsive, relevant, and robust is an important element
f the ODPRN’s success to date.
In this collaboration, various elements have stream-
ined the process of translating evidence into policy. First,
he partners found it necessary to be responsive to each
ther’s needs. Policymakers require analyses quickly to uti-
ize current research results in policymaking. Researchers
equire clear study objectives and must ensure that sci-
ntiﬁc output is of high quality and rigor. At the outset
f collaboration, the ODPRN and OPDP acknowledged one
nother’s speciﬁc requirements and sought to create a pro-
ess that would meet these needs. For example, the ODPRN
earned how to work with the OPDP to clarify research
bjectives through intensive communication, the creation
f documentation such as project proposals, and oppor-
unities to increase policymaker knowledge on research
ethods (e.g. through “lunch and learn” sessions for OPDP
embers). This acknowledgement of needs and establish-
ent of processes to address them characterizes mature,
uccessful relationships between researchers and policy-
akers [12].
Moreover, the ODPRN and OPDP were required to
nderstand the environments in which each partner works
nd operates. Perhaps one of the greater challenges for the
DPRN was realizing that evidence is not often the primary
river of policymaking [7], which can hinder the process
f utilizing ODPRN research results in evidence-informed17 (2014) 392–398 397
policymaking. One such example involved an analysis of
blood glucose test strips (BGTS) for patients with diabetes
in Ontario. BGTS are commonly prescribed to patients with
diabetes, but have limited clinical beneﬁt to certain groups
[26,27], leading to potential overuse and signiﬁcant costs
to the healthcare system. The ODPRN analyzed potential
cost avoidance related to hypothetical scenarios involving
changes to prescribing of BGTS and reported these ﬁnd-
ings in 2009 [28]. The study identiﬁed up to $300 million
CAD in potential cost savings over 5 years; however a
policy designed to set maximum quantity limits for reim-
bursement of these products was  not announced until the
spring of 2013 [29]. The slow adoption of evidence was
likely due to factors including MOHLTC’s concern about the
acceptability of the proposed options and a failure to imple-
ment similar policy options in other Canadian jurisdictions.
ODPRN researchers learned to recognize that policymak-
ing may  be delayed until the timing and political climate is
optimal [30]. Acceptance of this policymaker culture was
facilitated by the structure of the ODPRN, which enables
researchers to engage in academic work independent of
OPDP requests and ensures that the ODPRN can still pro-
duce impactful research without relying on the OPDP to
initiate requests or implement policy actions.
Finally, as with other researchers who  have engaged
with policymakers in research processes [12], effective
communication was  perhaps one of the most important
factors in overcoming barriers and developing a successful
partnership. To address this challenge, ODPRN members
established open, early and frequent communication with
the OPDP. Both partners recognized that dedicated time
was required on both ends to facilitate communication;
therefore, ensuring the availability of key contacts for
both groups was  essential for the ODPRN and OPDP to
strengthen their collaboration.
4.2. Limitations
Assessing the impact of ODPRN research is limited in
part by the dearth of available and meaningful indicators
for assessing policy impact. The ODPRN is currently assess-
ing impact by tracking the number of citations of ODPRN
research in policymaker documents, and obtaining poli-
cymaker feedback through personal communication and
surveys. In the future, the ODPRN will expand its eval-
uation framework to better capture the policy impact of
its research. Another limitation of this paper is that infor-
mation on meaningful clinical and economic outcomes of
policy decisions impacted by ODPRN research is not yet
available for some ODPRN studies; however, the ODPRN is
initiating an evaluation of policy decisions related to their
research.
5. Conclusions
Collaborative research processes can produce mutually
beneﬁcial partnerships between researchers and policy-
makers. Researchers at the ODPRN have engaged OPDP
policymakers in an innovative approach to conducting and
utilizing research evidence in policymaking, starting with
collaboratively deﬁning research questions, and ending
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with the dissemination of research results. Between these
two key activities, the ODPRN conducts a rapid-research
process that enhances the timeliness of dissemination.
Overall, the ongoing ODPRN—OPDP collaboration depicts
a partnership in which the information needs of policy-
makers – i.e., current, relevant, and scientiﬁcally rigorous
research in a timely manner – are satisﬁed. The ODPRN’s
scientiﬁc expertise and ownership of the research pro-
cess ensures that the ﬁndings maintain a high level of
quality and independence. The described research pro-
cesses and lessons learned throughout ﬁve years of
researcher–policymaker partnership will be valuable to
those seeking to enhance evidence uptake in policymak-
ing for immediate policy needs. Effective integration of
research into policymaking will lead to informed decisions
that profoundly affect the well-being of society at large.
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